Clinical Trial Update: A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 [Phase 2]

View source ↗

Summary

This Phase 2 study evaluated RO5024048 in combination with peginterferon alfa-2a (Pegasys) and ribavirin (Copegus) in patients with chronic hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)
• RO5024048

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED